How India Exports Burnol to the World

As of March 2026, Burnol does not have an approved Abbreviated New Drug Application (ANDA) listed in the FDA's Orange Book. This indicates that Burnol has not undergone the FDA's rigorous review process for generic drug approval in the United States. Consequently, Burnol is not authorized for marketing in the U.S. under the ANDA pathway.

Given that the United States accounted for 4.5% of Burnol's exports from India between 2022 and 2026, it is imperative for exporters to ensure compliance with FDA regulations. This includes obtaining the necessary approvals and adhering to import requirements to avoid potential import alerts or enforcement actions.

In the European Union (EU) and the United Kingdom (UK), medicinal products like Burnol require marketing authorization before they can be marketed. This process involves a comprehensive evaluation of the product's quality, safety, and efficacy. As of March 2026, there is no publicly available information indicating that Burnol has obtained such authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Manufacturers intending to market Burnol in these regions must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA. This ensures that products are consistently produced and controlled according to quality standards appropriate for their intended use.

Burnol is not listed in the World Health Organization's (WHO) Model List of Essential Medicines as of the latest edition. Additionally, there is no indication that Burnol has undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products.

Regarding pharmacopoeial standards, Burnol's active ingredients should comply with the specifications outlined in recognized pharmacopoeias such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the product's quality and consistency across different markets.

In India, Burnol is classified as an over-the-counter (OTC) medication, allowing it to be sold without a prescription. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, Burnol is not listed under the DPCO's price control list, indicating that its pricing is not subject to government-mandated ceilings.

For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) to ensure compliance with export regulations. This certificate is essential for the lawful export of pharmaceutical products from India.

As of March 2026, there are no active patents or exclusivity rights associated with Burnol. This absence of patent protection allows multiple manufacturers to produce and market generic versions of Burnol, leading to increased competition in the market.

In August 2025, the FDA approved an ANDA for Fosfomycin Tromethamine Granules for Oral Solution, 3 grams (Single-Dose Sachet), submitted by Aurobindo Pharma USA, Inc. This approval underscores the FDA's ongoing efforts to facilitate the availability of generic medications in the U.S. market.

In November 2025, the UK's Food Standards Agency (FSA) implemented the Genetic Technology (Precision Breeding) Regulations 2025, allowing businesses to apply for marketing authorizations for Precision Bred Organisms (PBOs) in food and feed. This regulatory development reflects the UK's commitment to advancing genetic technologies in the food sector. (food.gov.uk)

In December 2025, the FSA updated its guidance on the application process for PBOs, emphasizing the importance of conducting a Tier 1 safety assessment and obtaining a marketing notice from the Department for Environment, Food & Rural Affairs (Defra) before applying for authorization. This update aims to streamline the application process and ensure the safety of PBOs in the market. (food.gov.uk)

In January 2026, the FSA provided guidance on the transportation of 'above temperature' meat from red meat slaughterhouses, outlining the application process for authorizations to transport partially chilled meat above the standard temperature requirements. This guidance aims to ensure food safety while accommodating specific technological needs in meat processing. (food.gov.uk)

In February 2026, the FSA updated its guidance on pet food labeling, emphasizing the requirements for declaring ingredients and the option to declare by category. This update aims to provide clarity to manufacturers and ensure transparency for consumers. (food.gov.uk)

These developments highlight the dynamic nature of the pharmaceutical and food regulatory landscape, underscoring the importance of staying informed about policy changes and approvals that may impact market access and compliance requirements.

Burnol, a topical antiseptic cream, relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) predominantly sourced from China and India. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This heavy reliance on Chinese suppliers exposes the supply chain to potential disruptions. For instance, in 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP), highlighting ongoing quality concerns.

India's dependence on China for APIs is substantial. In 2023-24, China accounted for 43.45% of India's pharmaceutical imports, amounting to $3.6 billion. This overreliance poses risks, as any disruption in Chinese supply chains—due to regulatory actions, geopolitical tensions, or other factors—can significantly impact the availability and cost of essential raw materials for Burnol production.

Our proprietary trade data indicates that the top five exporters of Burnol from India account for 35.3% of total exports, with STAR EXPORTS leading at a 30% share. This concentration suggests a moderate risk, as reliance on a limited number of suppliers can lead to supply chain vulnerabilities if any of these key exporters face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic API production and reduce import dependence. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, which are essential for various antibiotics. While these initiatives aim to enhance self-reliance, their impact on reducing supplier concentration for Burnol's raw materials remains to be fully realized.

Recent geopolitical events have further strained global supply chains. In March 2026, the Strait of Hormuz crisis led to significant disruptions in maritime transit, affecting about 20% of the world's daily oil supply and causing a sharp decline in shipping activities. Such disruptions can lead to increased shipping costs and delays, impacting the timely export of Burnol to key markets.

Additionally, tensions in the Red Sea and the Strait of Hormuz have raised concerns about supply chain stability. Major shipping firms have suspended operations in these areas, leading to rerouted shipments and longer transit times. These factors contribute to increased costs and potential delays in delivering Burnol to international markets.

• Diversify Supplier Base: Identify and qualify additional suppliers for APIs and KSMs to reduce dependence on a limited number of sources.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in domestic manufacturing capabilities for critical raw materials.

• Strengthen Quality Assurance: Implement robust quality control measures to ensure compliance with international standards, mitigating risks associated with regulatory actions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains, enabling proactive risk management.

• Develop Contingency Plans: Create and regularly update contingency plans to address potential disruptions in raw material supply and shipping routes, ensuring business continuity.

RISK_LEVEL: MEDIUM